Send to

Choose Destination
J Am Vet Med Assoc. 1998 Dec 15;213(12):1760-6.

Efficacy of clomipramine in the treatment of canine compulsive disorder.

Author information

Department of Animal and Poultry Science, Ontario Agricultural College, Guelph, Canada.



To assess the efficacy of clomipramine for treatment of canine compulsive disorder (CCD).


Randomized, placebo-controlled, double-blind, balanced AB-BA crossover clinical study.


51 dogs with CCD.


Dogs were given clomipramine (3 mg/kg [1.3 mg/lb] of body weight, PO, q 12 h) for 4 weeks and placebo for 4 weeks. At the end of each treatment each owner rated the severity of their dog's behavior, using 2 validated rating scales. Statistical analysis was made by ordinal regression. Compliance, adverse effects, and the effectiveness of masking were also assessed. Each dog's behavior was reevaluated 1 to 2 years after completing the study.


Behaviors included spinning (n = 17) and self-mutilation by licking (acral lick dermatitis, 12). Both rating scales demonstrated a treatment effect. Compliance was satisfactory, and masking was effective. Sedation and reduced appetite were reported more commonly when dogs were given clomipramine than when they were given placebo. Forty-five dogs available for follow-up evaluation still had their behaviors; 6 dogs were lost to follow-up evaluation.


Results suggest that clomipramine was effective in dogs with CCD and was not associated with serious adverse effects. However, treatment for 4 weeks was not curative. Behavior modification is likely to be necessary to manage CCD.

[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center